Highlights

• Sigma Healthcare shares traded at AUD 2.76, declining 5.48% in the latest session amid profit-taking and sector rotation.
• The company reported strong half-year financial results with normalised EBIT up 18.7% and revenue growth of 14.9%.
• Expansion of the Chemist Warehouse network and international store rollout continued alongside integration progress and synergy delivery.

Sigma Healthcare Ltd (ASX: SIG) recorded a decline in its latest trading session, with shares closing at AUD 2.76, down 5.48% or 0.16 AUD as of 10 June 2026. The movement reflects a period of heightened volatility as investors reassess valuation positioning following a strong earnings cycle and ongoing post-merger integration activity.

Company Overview and Business Structure

Sigma Healthcare operates as a diversified healthcare distribution and retail pharmacy group in Australia, with its core platform anchored by the Chemist Warehouse branded network. The company’s business model spans wholesale pharmaceutical distribution, retail pharmacy operations, and international expansion of its branded retail footprint.

The integration of Chemist Warehouse into Sigma’s structure has materially reshaped the company’s earnings profile, creating a vertically integrated healthcare retail and distribution platform. This model combines high-volume pharmacy retail sales with supply chain and wholesale distribution capabilities.

The business operates within a highly regulated healthcare retail environment, where revenue growth is driven by prescription volumes, consumer health product demand, and expansion of retail pharmacy networks across domestic and international markets.

Half-Year Financial Performance and Growth Drivers

For the half year ended 31 December 2025 (1H26), Sigma Healthcare reported a period of strong financial expansion across key metrics. Normalised EBIT rose 18.7% to $582.9 million, while normalised net profit after tax increased 19.2% to $392.0 million. Revenue reached $5.5 billion, representing growth of 14.9% compared to the prior corresponding period.

This performance was primarily driven by continued expansion and sales momentum across the Chemist Warehouse branded store network in Australia, where sales increased 17.2%. Like-for-like sales growth of 15.0% indicated sustained demand within existing store formats, reflecting consistent consumer engagement within the pharmacy retail segment.

International operations also contributed to overall growth, with retail network sales increasing 24.5% and like-for-like international sales rising 11.1%. These figures highlight increasing geographic diversification of the business, particularly across New Zealand and Ireland, where store expansion programs remain active.

Operational efficiency also improved during the period, with operating leverage contributing to margin expansion. Distribution volumes increased to 298 million units, while cost growth remained comparatively subdued, reflecting scale benefits across the supply chain.

Chemist Warehouse Expansion and Retail Network Growth

A central component of Sigma’s growth strategy remains the continued expansion of the Chemist Warehouse branded network. During the reporting period, the Australian store network expanded to 550 locations following the addition of 13 new stores.

The company has also focused on portfolio simplification and brand consolidation, including the conversion of MyChemist franchise stores into Amcal and Discount Drug Stores (DDS) formats. This restructuring is intended to streamline brand architecture while maintaining multi-brand retail coverage across different customer segments.

Product strategy has also contributed to revenue expansion, with more than 400 new owned and exclusive products introduced during the half. Private label and exclusive offerings accounted for a growing share of sales, reflecting ongoing efforts to enhance category breadth and margin mix within the retail portfolio.

International expansion remains a key growth lever. In New Zealand, the network expanded to 70 stores following nine new openings, while Ireland reached 17 stores with additional openings planned. These markets are supported by emerging supply chain infrastructure, including the establishment of distribution capabilities in Ireland.

Integration Progress and Synergy Realisation

Integration of the combined Sigma-Chemist Warehouse business continues to progress, with management reporting $13 million in early synergies achieved during the half. The company has reiterated a long-term synergy target of $100 million annually by FY29.

These integration benefits are expected to be driven by supply chain optimization, procurement efficiencies, and rationalization of distribution infrastructure. The company’s scale advantage is becoming increasingly relevant, particularly as unit volumes continue to grow across both retail and wholesale channels.

Operating cash flow of $317.4 million during the period reflects continued cash generation capacity, supporting both integration investment and balance sheet flexibility. Net debt declined to $635.1 million, with leverage metrics remaining at relatively conservative levels compared to earnings generation.

The company also maintained a dividend payout consistent with its policy range, reflecting confidence in cash flow stability despite ongoing integration expenditure.

Sector Context: Pharmacy Retail and Distribution Trends

The pharmacy retail sector in Australia continues to evolve toward greater consolidation and vertical integration. Large-scale operators such as Sigma Healthcare are increasingly leveraging scale advantages to optimize procurement, distribution, and retail operations.

The integration of wholesale and retail functions allows for improved margin capture across the value chain, although it also introduces complexity in execution and operational coordination. International expansion further adds layers of regulatory and logistical considerations.

Growth in demand for prescription medicines, over-the-counter health products, and specialty pharmaceuticals continues to underpin sector revenue stability. However, competition within retail pharmacy remains structurally intense, with pricing dynamics and consumer accessibility playing central roles in market share outcomes.

Sigma’s expansion into international markets reflects a broader strategy of geographic diversification, aiming to reduce reliance on domestic performance while leveraging the Chemist Warehouse brand model in new regions.

Risk Considerations and Execution Factors

The company’s forward outlook is shaped by several operational and strategic considerations. Integration execution remains central, particularly in achieving projected synergy targets over the medium term. Delays or inefficiencies in integration could influence margin outcomes and investor expectations.

Retail expansion across international markets introduces additional execution variables, including regulatory compliance, supply chain scaling, and local market adaptation. These factors can influence the pace at which new stores contribute meaningfully to earnings.

Margin sustainability is another area of focus, particularly following periods of strong earnings growth driven by mix shifts and scale benefits. As growth normalizes, maintaining operating leverage will depend on continued efficiency improvements and product mix optimization.

Conclusion

Sigma Healthcare Ltd is currently navigating a transition phase characterized by strong underlying financial performance alongside ongoing integration and expansion initiatives. The latest share price decline to AUD 2.76 reflects short-term market recalibration following a period of robust earnings growth and sustained operational momentum.

While the company continues to deliver double-digit growth across revenue and profitability metrics, investor sentiment appears increasingly focused on the durability of these trends and the execution pathway toward long-term synergy realization. The combination of domestic retail strength and international expansion positions the company within a structurally growing healthcare distribution and pharmacy retail sector, with market attention now centered on execution consistency and integration outcomes.